Sandeep Kishore

Associate Professor

Sandeep (Sunny) P. Kishore is a physician-scientist and Associate Professor at UCSF who is committed to transforming how we predict, prevent and control chronic disease. His work lies at the convergence of digital innovation, population health and precision medicine to build systems that proactively intervene when it counts most.

At UCSF, he serves as the clinical lead for Jupyter Health, heading a cross-functional team focused on shifting care for conditions like hypertension, obesity and diabetes from reactive to proactive. His team focuses on interpretable data from wearables, digital biomarkers and personalized decision algorithms across the disease continuum.

He co-led the development of a scalable treatment algorithm to drive the digital transformation of blood pressure control across the University of California, the nation’s largest academic health system, encompassing 10 hospitals and 1,000 care delivery sites.

Previously, he modernized the WHO Essential Medicines List to include tools for early, equitable access to chronic disease medications and served as a technical advisor to Resolve to Save Lives targeting the prevention of 100 million deaths through improved cardiovascular health. He also founded the Young Professionals Chronic Disease Network, the world’s first and largest network of early career health professionals focused on chronic disease prevention and control.

He has authored over 70 articles in esteemed medical journals including NEJM, JAMA and The Lancet as well as in popular publications such as Scientific American, and has spoken at TEDMED and the United Nations. His honors include the Sarber Award for the top PhD student in microbiology at the American Society of Microbiology, selection as an Emerging Leader at the National Academy of Medicine, a Fellow at the MIT Dalai Lama Center, and as a Paul & Daisy Soros Fellow for New Americans. He completed his MD-PhD at Weill Cornell/Rockefeller/Sloan-Kettering, master’s at Oxford as the Usher Cunningham Scholar and clinical training in internal medicine at Yale and at Harvard’s Brigham & Women’s Hospital.
Education
06/2021 - Residency, Brigham & Women's Hospital/Harvard Medical School
06/2015 - Internship, Yale School of Medicine/Yale New Haven
MD-PhD, 05/2014 - Medicine, Weill Cornell/ Rockefeller/ Sloan-Kettering Institute
M.Sc, 08/2006 - Immunology, University of Oxford
B.S., 05/2004 - Biology, Duke University
Publications

  1. Narang P, Marquez J, Rashidi N, Haar R, Kishore SP. Fixed-Dose Combinations for Hypertension: Barriers to Use and Opportunities for Health Systems. Journal of clinical hypertension (Greenwich, Conn.) 2026. PMID: 42227201


  2. Kishore SP, Martin HE, Friedberg N, Narang P, Sak R, Skootsky SA, UC Way Hypertension Initiative Medication Use Collaborators. Scalable treatment algorithm focused on hypertension management for the University of California. BMJ open quality 2026. PMID: 41850707


  3. Kishore SP, Kocher R. The Hypertension Control Paradox - Why Is America Stuck? The New England journal of medicine 2026. PMID: 41586539


  5. Heller DJ, Hudspeth JC, Kishore SP, Mercer T, Schwartz JI, Rabin TL. Bringing Generalists to Global Health: a Missed Opportunity and Call to Action. Journal of general internal medicine 2023. PMID: 38135777


  6. Kishore SP. Global NCD policy implementation stalls in the modern era. The Lancet. Global health 2023. PMID: 36925158


  7. Garg A, Murphy A, Krishna A, Sahoo SK, Huffman MD, Kishore SP, Shivashankar R. Essential medicines for cardiovascular diseases in India: Rapid appraisal of policies and processes at the subnational level. The National medical journal of India 2023. PMID: 37167513


  8. Agarwal A, Husain MJ, Datta B, Kishore SP, Huffman MD. Access to Heart Failure Medicines in Low- and Middle-Income Countries: An Analysis of Essential Medicines Lists, Availability, Price, and Affordability. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2022. PMID: 35249355


  9. Groden P, Capellini A, Levine E, Wajnberg A, Duenas M, Sow S, Ortega B, Medder N, Kishore S. The success of behavioral economics in improving patient retention within an intensive primary care practice. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2021. PMID: 34937551


  10. Jezmir JL, Bharadwaj M, Chaitoff A, Diephuis B, Crowley CP, Kishore SP, Goralnick E, Merriam LT, Milliken A, Rhee C, Sadovnikoff N, Shah SB, Gupta S, Leaf DE, Feldman WB, Kim EY, STOP-COVID Investigators. Performance of crisis standards of care guidelines in a cohort of critically ill COVID-19 patients in the United States. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2021. PMID: 34337554


  11. Bharadwaj M, Jezmir JL, Kishore SP, Winkler M, Diephus B, Haider H, Crowley CP, Pinilla-Vera M, Varon J, Baron RM, Feldman WB, Kim EY. Empirical Assessment of U.S. Coronavirus Disease 2019 Crisis Standards of Care Guidelines. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2021. PMID: 34286282


  12. Armstrong-Hough M, Sharma S, Kishore SP, Akiteng AR, Schwartz JI. Variation in the availability and cost of essential medicines for non-communicable diseases in Uganda: A descriptive time series analysis. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2020. PMID: 33362249


  13. Newman D, Tong M, Levine E, Kishore S. Correction: Prevalence of multiple chronic conditions by U.S. state and territory, 2017. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2020. PMID: 32970771


  14. Salam A, Huffman MD, Kanukula R, Hari Prasad E, Sharma A, Heller DJ, Vedanthan R, Agarwal A, Rodgers A, Jaffe MG, R Frieden T, Kishore SP. Two-drug fixed-dose combinations of blood pressure-lowering drugs as WHO essential medicines: An overview of efficacy, safety, and cost. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2020. PMID: 32815663


  15. Jezmir JL, Bharadwaj M, Kishore SP, Winkler M, Diephuis B, Kim EY, Feldman WB. Empirical Assessment of COVID-19 Crisis Standards of Care Guidelines. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2020. PMID: 32511478


  16. Newman D, Tong M, Levine E, Kishore S. Prevalence of multiple chronic conditions by U.S. state and territory, 2017. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2020. PMID: 32369509


  17. Husain MJ, Datta BK, Kostova D, Joseph KT, Asma S, Richter P, Jaffe MG, Kishore SP. Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2020. PMID: 32338557


  18. Schwarz D, Dhungana S, Kumar A, Acharya B, Agrawal P, Aryal A, Baum A, Choudhury N, Citrin D, Dangal B, Dhimal M, Gauchan B, Gupta T, Halliday S, Karmacharya B, Kishore S, Koirala B, Kshatriya U, Levine E, Maru S, Rimal P, Sapkota S, Schwarz R, Shrestha A, Thapa A, Maru D. An integrated intervention for chronic care management in rural Nepal: protocol of a type 2 hybrid effectiveness-implementation study. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2020. PMID: 31996250


  19. Kishore SP, Majumdar UB. Learning from progress: global NCD policy implementation at national level. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2019. PMID: 31813789


  20. Heller DJ, Kumar A, Kishore SP, Horowitz CR, Joshi R, Vedanthan R. Assessment of Barriers and Facilitators to the Delivery of Care for Noncommunicable Diseases by Nonphysician Health Workers in Low- and Middle-Income Countries: A Systematic Review and Qualitative Analysis. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2019. PMID: 31790570


  21. Majumdar UB, Hunt C, Doupe P, Baum AJ, Heller DJ, Levine EL, Kumar R, Futterman R, Hajat C, Kishore SP. Multiple chronic conditions at a major urban health system: a retrospective cross-sectional analysis of frequencies, costs and comorbidity patterns. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2019. PMID: 31619421


  22. Frieden TR, Varghese CV, Kishore SP, Campbell NRC, Moran AE, Padwal R, Jaffe MG. Scaling up effective treatment of hypertension-A pathfinder for universal health coverage. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2019. PMID: 31544349


  23. Salam A, Kanukula R, Atkins E, Wang X, Islam S, Kishore SP, Jaffe MG, Patel A, Rodgers A. Efficacy and safety of dual combination therapy of blood pressure-lowering drugs as initial treatment for hypertension: a systematic review and meta-analysis of randomized controlled trials. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2019. PMID: 30986788


  24. von Oettingen JE, Ginsburg O, Kishore SP, Pastakia SD, Schroeder LF, Milner DA, Vedanthan R. The AEIOU of essential diagnostics: align, expand, implement, oversee, and update. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2019. PMID: 31097269


  25. Kumar A, Schwarz D, Acharya B, Agrawal P, Aryal A, Choudhury N, Citrin D, Dangal B, Deukmedjian G, Dhimal M, Dhungana S, Gauchan B, Gupta T, Halliday S, Jha D, Kalaunee SP, Karmacharya B, Kishore S, Koirala B, Kunwar L, Mahar R, Maru S, Mehanni S, Nirola I, Pandey S, Pant B, Pathak M, Poudel S, Rajbhandari I, Raut A, Rimal P, Schwarz R, Shrestha A, Thapa A, Thapa P, Thapa R, Wong L, Maru D. Designing and implementing an integrated non-communicable disease primary care intervention in rural Nepal. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2019. PMID: 31139453


  26. Newman D, Levine E, Kishore SP. Prevalence of multiple chronic conditions in New York State, 2011-2016. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2019. PMID: 30730970


  27. Heller DJ, Kishore SP. Impacting Global Health Delivery Through Advocacy: The Case of Losartan. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2018. PMID: 30584029


  28. DiPette DJ, Skeete J, Ridley E, Campbell NRC, Lopez-Jaramillo P, Kishore SP, Jaffe MG, Coca A, Townsend RR, Ordunez P. Fixed-dose combination pharmacologic therapy to improve hypertension control worldwide: Clinical perspective and policy implications. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2018. PMID: 30480368


  29. Kishore SP, Salam A, Rodgers A, Jaffe MG, Frieden T. Fixed-dose combinations for hypertension. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2018. PMID: 30215377


  30. Hajat C, Kishore SP. The case for a global focus on multiple chronic conditions. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2018. PMID: 29989034


  31. Armstrong-Hough M, Kishore SP, Byakika S, Mutungi G, Nunez-Smith M, Schwartz JI. Disparities in availability of essential medicines to treat non-communicable diseases in Uganda: A Poisson analysis using the Service Availability and Readiness Assessment. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2018. PMID: 29420640


  32. Kishore SP, Blank E, Heller DJ, Patel A, Peters A, Price M, Vidula M, Fuster V, Onuma O, Huffman MD, Vedanthan R. Modernizing the World Health Organization List of Essential Medicines for Preventing and Controlling Cardiovascular Diseases. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2018. PMID: 29406862


  33. Kishore SP, Heller DJ, Vasan A. Beyond hypertension: integrated cardiovascular care as a path to comprehensive primary care. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2017. PMID: 29531421


  34. Heller DJ, Kishore SP. Closing the blood pressure gap: an affordable proposal to save lives worldwide. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2017. PMID: 29018587


  35. Marks VA, Latham SR, Kishore SP. On Essentiality and the World Health Organization's Model List of Essential Medicines. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2017. PMID: 29221540


  36. Jarvis JD, Obscherning E, Siegel K, Kishore SP. A Global Social Network to Catalyze Solutions for Chronic NCD: A Case Study on the Young Professionals Chronic Disease Network. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2016. PMID: 27938843


  37. Ruchman SG, Kishore SP, Singh P. A Platform to Accelerate Global Reductions in Chronic Diseases: Toward Action. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2016. PMID: 27938830


  38. Kishore SP, Belt R, Park PH. Noncommunicable Diseases: The Authors Reply. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2015. PMID: 26526266


  39. Siddharthan T, Ramaiya K, Yonga G, Mutungi GN, Rabin TL, List JM, Kishore SP, Schwartz JI. Noncommunicable Diseases In East Africa: Assessing The Gaps In Care And Identifying Opportunities For Improvement. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2015. PMID: 26355052


  40. Kishore SP, Kolappa K, Jarvis JD, Park PH, Belt R, Balasubramaniam T, Kiddell-Monroe R. Overcoming Obstacles To Enable Access To Medicines For Noncommunicable Diseases In Poor Countries. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2015. PMID: 26355060


  41. Jaacks LM, Ali MK, Bartlett J, Bloomfield GS, Checkley W, Gaziano TA, Heimburger DC, Kishore SP, Kohler RE, Lipska KJ, Manders O, Ngaruiya C, Peck R, Pena MB, Watkins DA, Siegel KR, Narayan KM. Global Noncommunicable Disease Research: Opportunities and Challenges. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2015. PMID: 26301624


  42. Carroll L, Ali MK, Cuff P, Huffman MD, Kelly BB, Kishore SP, Narayan KM, Siegel KR, Vedanthan R. Envisioning a transdisciplinary university. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2014. PMID: 25564706


  43. Beaglehole R, Bonita R, Ezzati M, Alleyne G, Dain K, Kishore SP, Horton R. NCD Countdown 2025: accountability for the 25 × 25 NCD mortality reduction target. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2014. PMID: 25012115


  44. Wynia MK, Kishore SP, Belar CD. A unified code of ethics for health professionals: insights from an IOM workshop. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2014. PMID: 24570240


  45. Ukaegbu UE, Kishore SP, Kwiatkowski DL, Pandarinath C, Dahan-Pasternak N, Dzikowski R, Deitsch KW. Recruitment of PfSET2 by RNA polymerase II to variant antigen encoding loci contributes to antigenic variation in P. falciparum. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2014. PMID: 24391504


  46. Matheka DM, Nderitu J, Vedanthan R, Demaio AR, Murgor M, Kajana K, Loyal P, Alkizim FO, Kishore SP. Young professionals for health development: the Kenyan experience in combating non-communicable diseases. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2013. PMID: 24262308


  47. Kishore S, Scott J. Global cancer disparity highlighted. Journal of neurosciences in rural practice 2013. PMID: 24174769


  48. Kishore SP, Basu S, Selvaraj S. Access to cancer medicines in India. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2013. PMID: 23561744


  49. Hogerzeil HV, Liberman J, Wirtz VJ, Kishore SP, Selvaraj S, Kiddell-Monroe R, Mwangi-Powell FN, von Schoen-Angerer T, Lancet NCD Action Group. Promotion of access to essential medicines for non-communicable diseases: practical implications of the UN political declaration. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2013. PMID: 23410612


  50. Kishore SP, Stiller JW, Deitsch KW. Horizontal gene transfer of epigenetic machinery and evolution of parasitism in the malaria parasite Plasmodium falciparum and other apicomplexans. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2013. PMID: 23398820


  51. Kishore S, Fetcho JR. Homeostatic regulation of dendritic dynamics in a motor map in vivo. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2013. PMID: 23803587


  52. Kolappa K, Henderson DC, Kishore SP. No physical health without mental health: lessons unlearned? "Are Telehealth Visits Feasible for Vulnerable Patients?" 2013. PMID: 23397342


  53. Francis ER, Goodsmith N, Michelow M, Kulkarni A, McKenney AS, Kishore SP, Bertelsen N, Fein O, Balsari S, Lemery J, Fitzgerald D, Johnson W, Finkel ML. The global health curriculum of Weill Cornell Medical College: how one school developed a global health program. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2012. PMID: 22929431


  54. Basu S, Andrews J, Kishore S, Panjabi R, Stuckler D. Comparative performance of private and public healthcare systems in low- and middle-income countries: a systematic review. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2012. PMID: 22723748


  55. Huffman MD, Siegel KR, Kishore SP, Bitton A. Regarding the prevention of global chronic disease: academic public health's new frontier. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2011. PMID: 22021284


  56. Khandelwal S, Huffman MD, Shah S, Kishore S, Siegel K. Non-communicable, chronic disease training and education needs in India. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2011. PMID: 25691045


  57. Kishore S, Siegel KR, Kelly B, Vedanthan R, Ali MK, Koplan J, Narayan KM, Fuster V. Preparing the university community to respond to 21st century global public health needs. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2011. PMID: 25691043


  58. Siegel KR, Kishore SP, Huffman MD, Aitsi-Selmi A, Baker P, Bitton A, Mwatsama M, Ding EL, Feigl AB, Khandelwal S, Rapkin N, Seligman B, Vedanthan R. Trans-Disciplinary Education and Training for NCD Prevention and Control. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2011. PMID: 25691044


  59. Kishore SP, Siegel KR, Ahmad A, Aitsi-Selmi AA, Ali MK, Baker P, Basu S, Bitton A, Bloomfield GS, Bukhman G, Emery E, Feigl AB, Grepin K, Huffman MD, Kajana K, Khandelwal S, Kolappa K, Liu C, Lokhandwala N, Marwah V, Mwatsama M, Novak N, Nundy S, Park PH, Perez CP, Price MR, Rapkin N, Rice H, Seligman B, Shah S, Silva Jd, Sridhar D, Stuckler D, Vedanthan R, Zaman J, Young Professionals’ Chronic Disease Network. Youth manifesto on non-communicable diseases. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2011. PMID: 25691046


  60. Kishore SP, Vedanthan R, Fuster V. Promoting global cardiovascular health ensuring access to essential cardiovascular medicines in low- and middle-income countries. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2011. PMID: 21565635


  61. Siegel KR, Feigl AB, Kishore SP, Stuckler D. Misalignment between perceptions and actual global burden of disease: evidence from the US population. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2011. PMID: 21562634


  62. Finch TH, Chae SR, Shafaee MN, Siegel KR, Ali MK, Tomei R, Panjabi R, Kishore SP. Role of students in global health delivery. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2011. PMID: 21598264


  63. Kishore SP, Bitton A, Cravioto A, Yach D. Enabling access to new WHO essential medicines: the case for nicotine replacement therapies. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2010. PMID: 21092092


  64. Maciag K, Kishore SP. Generic drugs for developing nations. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2010. PMID: 20531275


  65. Chen CE, Gilliland CT, Purcell J, Kishore SP. The silent epidemic of exclusive university licensing policies on compounds for neglected diseases and beyond. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2010. PMID: 20361025


  66. Kishore SP, Tavera G, Hotez PJ. The global health crisis and our nation's research universities. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2010. PMID: 20186327


  67. Kishore SP, Perkins SL, Templeton TJ, Deitsch KW. An unusual recent expansion of the C-terminal domain of RNA polymerase II in primate malaria parasites features a motif otherwise found only in mammalian polymerases. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2009. PMID: 19449052


  68. Kishore SP, Herbstman BJ. Adding a medicine to the WHO model list of essential medicines. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2009. PMID: 19223877


  69. Kishore SP, Dhadialla PS. A student-led campaign to help tackle neglected tropical diseases. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2007. PMID: 17676947


  70. Kishore SP, Bungum MK, Platt JL, Brunn GJ. Selective suppression of Toll-like receptor 4 activation by chemokine receptor 4. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2005. PMID: 15670831